HROW – harrow health, inc. (US:NASDAQ)
Stock Stats
News
How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story [Yahoo! Finance]
Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS [Seeking Alpha]
Harrow to Present at Two Investor Conferences in December
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
Harrow (NASDAQ:HROW) had its price target raised by analysts at LADENBURG THALM/SH SH from $64.00 to $66.00. They now have a "buy" rating on the stock.
Form 4 HARROW, INC. For: Dec 12 Filed by: BOLL ANDREW R.
Form 4 HARROW, INC. For: Dec 12 Filed by: BAUM MARK L
Form 8-K HARROW, INC. For: Nov 17
Form 10-Q HARROW, INC. For: Sep 30
Form 8-K HARROW, INC. For: Aug 11
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.